This is BrainsWay’s global website. The website includes information on clinical indications that were not cleared by the FDA and are considered investigational by the U.S. medical device regulations. The FDA cleared BrainsWay D treatment of Major Depression in patients who failed to respond to one or more anti-depressants in the current episode.
The purpose of the study is to explore the efficacy and safety of HBLPADD Coil Deep TMS in subjects with ADHD. The Patient Population is 40 patients diagnosed with ADHD. The patients will be of all racial, ethnic and gender categories, ranging from 18 to 65 years of age.
The Structure of The study is a randomized, prospective, 5 weeks, double blind study. The treatment administrator and the study personnel and patients will be masked to the treatment being administrated. The study group will receive active Deep TMS treatment and the control group will receive an inactive, sham treatment.
The Primary Outcome Measure is will be examined by the change in the CAARS questionnaire from the baseline visit to the termination visit in the treatment group compared to the control group.
Principal Investigator: Prof. Hilik Levkovitz